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Abstract
Background: The recent Ebola epidemic in western Africa developed into an acute public health emergency of
unprecedented level in modern times. The treatment provided in most cases has been limited to supportive care,
as no approved therapies are available to date. Several established, licenced drugs have been suggested as
potential repurposed therapeutic agents for Ebola. However, scientific data on their efficacy in treating Ebola is
limited. The purpose of this review is to systematically assess scientific evidence on potential drugs targeting Ebola.
In specific, we aim to (1) identify drug library screens involving therapeutic agents targeting the Ebola virus, (2) list
potential approved drugs identified from drug screens and review their mechanism of action against the Ebola
virus and (3) summarise the outcome of preclinical and clinical trials investigating approved drugs targeting the
Ebola virus.
Methods/design: We will develop comprehensive systematic search strategies and will perform a systematic
literature search in MEDLINE, Embase and Cochrane Central Register of Controlled Trials (CENTRAL). Two authors
will independently screen the titles, abstracts and the references of all selected articles on the basis of inclusion
criteria. These include any available drug screening, preclinical studies and clinical studies examining the efficacy of
approved therapeutic agents targeting the Ebola virus. There will be no restrictions on the type of participants, the
type of comparator, time or setting. Data extraction and quality assessment will be undertaken by two review
authors working independently.
Discussion: This systematic review will provide systematic knowledge on potential repurposed therapeutic agents
targeting Ebola. It aims to help guide future investigations on repurposed drugs and avoid repetitive studies.
Systematic review registration: PROSPERO CRD42015024349
Keywords: Ebola virus, Ebola virus disease, Ebola haemorrhagic fever, Pharmacotherapy, Drug repurposing, Anti-
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Background
The recent Ebola epidemic in western Africa developed
into an unprecedented global public health crisis with sig-
nificant humanitarian consequences. As of October 25,
2015, a total of 28,575 infected patients and 11,313 deaths
have been documented worldwide [1]. The treatment pro-
vided in the great majority of cases has been limited to
supportive care as no approved therapies or vaccines are
available. The recommended supportive therapy includes
balancing the patient’s fluids and electrolytes, maintaining
the blood pressure and oxygen supply, as well as treating
for any accompanying complications [2].
With a case fatality rate for the Ebola virus disease
(EVD) averaging 50 % [2], there is increasing pressure to
develop targeted therapeutic agents. This has also trig-
gered an intensive debate on the use of drug repurposing
in Ebola [3]. The concept of drug repurposing, also
known as drug repositioning, refers to the application of
established drugs in novel therapeutic indications that
have not been previously approved [4]. In addition to
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fast-tracking the development of anti-Ebola drugs, many
scientists have endorsed the clinical use of repurposed
drugs to treat EVD [3, 5, 6].
Various readily available drugs have been examined as
potential therapeutic agents targeting the Ebola virus life
cycle or the associated immune reaction. These include
blood transfusions from EVD survivors, antimalarial drug
chloroquine and antiarrhythmic agents such as amioda-
rone, amongst many others [6]. These therapeutic agents
have already passed essential toxicity and safety tests and
can bypass phase I and phase IIa clinical trials. In addition,
previous clinical data and experience provide valuable in-
formation on the drug’s pharmacokinetic behaviour and
long-term toxicity [4]. The presence of an established
manufacturing and distribution networks for these drugs
is of particular importance as it allows for rapid availability
in urgent cases [7]. Nonetheless, scientific evidence on the
efficacy of various repurposed drugs in treating Ebola is
limited, and additional investigations to justify their use in
the treatment of EVD are necessary.
On the other hand, conventional drug development re-
quires a lengthy and costly period to establish the safety
and dosage of novel drugs as well as ensuring availability
in sufficient amounts. It is estimated that it takes more
than 10 years and over 2 billion US dollars to develop a
new pharmaceutical drug [8]. The recent Ebola outbreak
has revealed that, despite a fast-track programme to ac-
celerate the development of experimental anti-Ebola
drugs and vaccines, delays at different stages of develop-
ment and production may have occurred [9, 10].
So far, a variety of literature reviews have been pub-
lished on therapeutic targets for EVD, some of which
also include an overview of possible candidates for drug
repurposing [6, 11–15]. However, no systematic review
dedicated to repurposed therapeutic agents targeting
Ebola exists to date. Given the lack of a systematic as-
sessment of current evidence, we aim to systematically
review current scientific evidence on potential repur-
posed drugs targeting Ebola.
Objectives
The aim of this review is as follows:
1. To identify available library screens involving
repurposed therapeutic agents targeting the Ebola
virus. These include virtual or high throughput
screens which allow researchers to identify a subset
of compounds that are likely to bind to a target in
the Ebola virus, such as an enzyme or a receptor.
2. To list therapeutic agents, approved by the Food and
Drug Administration (FDA) or an equivalent agency,
with potential anti-Ebola virus effects identified from
drug screens and to report their proposed mechanism
of action.
3. To summarise the outcome of preclinical and
clinical trials investigating repurposed drugs
targeting the Ebola virus.
With our proposed systematic review, we hope to pro-
vide clinicians and scientists with an overview of scien-
tific evidence on potential repurposed drugs targeting
the Ebola virus, with a particular focus on the outcome
of preclinical and clinical trials. This will not only guide
future investigations aiming at providing further evi-




The proposed review protocol conforms to the Preferred
Reporting Items in Systematic Reviews and Meta-
analyses (PRISMA) statement and the associated check-
list [16]. The protocol is registered in the International




The following are our inclusion criteria:
 Studies on drug library screens which yielded at
least one approved therapeutic agent targeting the
Ebola virus.
 Any available preclinical and clinical studies
examining the efficacy of approved therapeutic
agents targeting the Ebola virus.
 Preclinical trials which may include studies on cell
cultures, on mouse models or non-human primates.
 Clinical trials on humans which may include
randomised controlled trials (RCTs), controlled
clinical trials (CCTs), prospective and retrospective
comparative cohort studies, as well as case-control
studies. Cross-sectional studies, case series and case
reports may also be included.
Study population, timing and setting
There will be no restrictions on the type of participants
in preclinical or clinical trials. In addition, there will be
no restrictions on the type of setting. We will include
studies published from 1976, the year of discovery of the
Ebola virus.
Types of intervention
We will include interventions involving drug library
screening, preclinical studies or clinical studies examin-
ing the use approved therapeutic agents targeting the
Ebola virus.
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Comparators
There will be no restrictions on the type of comparator.
Placebo, supportive care or other therapeutic interven-
tions will be accepted.
Outcomes
The primary outcomes will include mortality, sequelae
of the infection and serious adverse events. Secondary
outcomes include adverse events. Outcomes will be col-
lected as reported. We will extract outcomes in all data
forms (e.g. dichotomous, continuous) as reported in the
included studies.
Languages
We will include articles reported in the English, German,
French and Spanish languages. A list of possibly relevant ti-
tles in any other language will be provided as an appendix.
Publication status
We will include articles published in scientific journals
as well as unpublished ones.
Information sources
Literature search strategies will be developed using med-
ical subject headings (MeSH) and text words related to
the Ebola virus. We will perform a systematic literature
search in MEDLINE, Embase and Cochrane Central
Register of Controlled Trials (CENTRAL). Studies pub-
lished between January 1976 and the date the searches
are run will be sought.
To identify ongoing and unpublished studies, we will
search the World Health Organization (WHO) Inter-
national Clinical Trials Registry Platform (ICTRP), Clini-
calTrials.gov and EU Clinical Trials Register. In addition,
we will search the reference lists of selected studies as well
as the websites of regulatory authorities (US Food and
Drug Administration and European Medicine Agency).
Search strategy
A search strategy will be developed for each of the data-
bases with the help of an information specialist [see
Additional file 1]. The database records yielded by all
search strategies will be exported into EndNote, and du-
plicates will be removed manually. The results of our
database searches and records identified from other
sources will be documented and depicted in a PRISMA
flow diagram.
Study selection
Prior to formal screening, a preliminary study screening
spreadsheet [see Additional file 2: Table S1] will be used
by two authors (HS and OE) to carry out a pilot screen-
ing using 50 randomly chosen studies from the search
results. If necessary, the study selection spreadsheet will
be refined after the pilot screening. Following the pilot
screening, both authors will independently screen the ti-
tles and abstracts yielded by the search against the inclu-
sion criteria. In addition, they will screen the reference
lists of all selected articles. Studies selected at title and
abstract level will be further screened for eligibility by
assessing the full text of the article. We will seek add-
itional information from study authors where necessary
to resolve questions about eligibility. Opinion of a third
reviewer (SKL) will be sought to arrive at a consensus in
case of disagreement on a study for inclusion. We will
document the reasons for excluding trials at the full-text
screening level. Neither of the review authors will be
blind to the journal titles or to the study authors or in-
stitutions. We will report the results of the study selec-
tion process and reasons for exclusion at the full-text
screening level using a PRISMA flow diagram.
Data extraction
Initially, two authors (HS and OE) will independently
extract the names and active ingredients of all drugs tar-
geting the Ebola virus suggested by drug library screen-
ing studies. A preliminary data extraction spreadsheet
[see Additional file 3: Table S2] will be used to conduct a
pilot test carried out by both authors using five randomly
selected papers. The data extraction sheet will be refined
accordingly after the pilot studies. The refined spreadsheet
will be used by both authors to independently extract data
from all included preclinical and clinical trials. Opinion of
a third reviewer (SKL) will be sought to arrive at a consen-
sus in case of disagreement. Study authors will be con-
tacted for further clarification if necessary.
Qualitative data reported in studies included in the re-
view will be excluded from the review and thus will not be
extracted. However, if an included study draws conclusion
based on qualitative data, we will report those conclusions
separately in the characteristics of study table.
Data items
Following are the items we will extract from the differ-
ent types of studies [see Additional file 3: Table S2].
Study quality
The same reviewers involved in data extraction will in-
dependently evaluate the quality of eligible studies. In-
ternal validity of preclinical studies (animal studies) will
be assessed using the SYRCLE’s risk or bias tool [17]. As
per the instructions outlined in the Cochrane Handbook
for systematic reviews of interventions, the Newcastle-
Ottawa scale will be used to assess quality of non-
randomised studies. If an adequate number of rando-
mised controlled trials are identified in our search, the
Cochrane Collaboration’s tool for assessing risk of bias
will be used.
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Statistical analysis
We expect studies to be too heterogeneous to allow for a
quantitative summary of results. If, however, we find sub-
sets of studies to be homogeneous enough, we will per-
form a random effects meta-analysis for all primary
outcomes. Heterogeneity will be detected through visual
inspection of the forest plots and by using a standard chi2
test with a significance level of P < 0.10. The I2 statistic will
be applied to quantify inconsistency across studies and to
assess the impact of heterogeneity on the meta-analysis.
I2 ≥ 50 % indicates substantial heterogeneity.
Subgroup analyses will be conducted on the primary
outcomes, whether meta-analysed or synthesised narra-
tively, if feasible. Subgroups investigated will be at least
age, sex and region.
Studies with separate control groups are likely to
measure the effect of treatment on a dichotomous or or-
dinal health outcome as a risk ratio, odds ratio or risk
difference between the treatment and control groups.
This review will prioritise risk ratios. In cases where a
risk ratio is not reported in a record, we will either cal-
culate it from data reported in the record or request a
risk ratio measure or the data required to calculate it
from the principal author of the record, contacting them
by email or phone, using the contact details provided in
the record. When included studies report treatment ef-
fects on continuous outcomes as mean differences be-
tween treatment and control groups, we will report the
mean difference. Where different scales are used for the
same outcome, the review will report the standardised
mean difference (Hedges’ g).
If a study presents adjusted and unadjusted treatment
effect measures, the review will report the adjusted mea-
sures. If only unadjusted treatment effect measures are
provided, but measures for between-group differences in
covariates at baseline and/or potential confounders are
also reported, then we will adjust the treatment effect
measure for these variables. However, if the required in-
formation for adjustment of treatment effect estimates is
not provided, we will request from the principal study
author by email or phone an adjusted treatment effect
estimate. If we are only able to obtain unadjusted treat-
ment effect measures, we will report and use these mea-
sures, with the appropriate caveats.
Intention-to-treat treatment effect measures will be
prioritised over other treatment effect measures. If feas-
ible, 95 % confidence intervals will be provided for each
treatment effect measures.
Discussion
The recent Ebola outbreak is an unprecedented public
health risk with a high mortality rate and no approved
targeted treatment to date. Repurposed therapeutic
agents represent a valid approach to finding a treatment
for EVD, and they offer significant advantages in terms
of saving time and financial resources. However, add-
itional scientific evidence on their efficacy is essential to
justify their use in the treatment of EVD.
This systematic review will give an overview of the
existing data on repurposed therapeutic agents targeting
Ebola. It will assess the current level of scientific evi-
dence for candidate therapeutic agents from the drug
screening stage to the clinical trial stage and will outline
the strengths and limitations of identified evidence. Fur-
thermore, this review will help expose areas for potential
research on repurposed drugs for the treatment of EVD,
hence guiding future investigations in this field. The lim-
itations and strengths of this review will be discussed,
and results from other relevant systematic reviews will
be compared to the results of this review.
Additional files
Additional file 1: Search strategies. Search strategies for Medline,
Embase and Central databases. (DOC 29 kb)
Additional file 2: Table S1. Study screening. Study screening
spreadsheet for the selection of eligible studies. (DOC 31kb)
Additional file 3: Table S2. Data items. Data items for extraction from
different types of selected studies. (DOC 35 kb)
Abbreviations
EVD: Ebola virus disease; FDA: Food and Drug Administration;
RCT: randomised controlled trials; CCT: controlled clinical trials;
PRISMA: Preferred Reporting Items in Systematic Reviews and Meta-analyses.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
HS and OE will design the study; acquire, analyse and interpret the data; and
draft the manuscript. All authors will contribute to the development of the
selection criteria, the risk of bias assessment strategy and data extraction
criteria. TJ will develop the search strategy and will carry out the search. SKL
will provide critical revision at different stages of research and of the drafted
manuscript. All authors will read, provide feedback and approve the final
manuscript.
Authors’ information
HS is currently a student at the professional master’s degree programme in
Public Health at the University of Düsseldorf in Germany. He is a senior
surgical resident at the surgical department of Klinikum Frankfurt Höchst in
Germany. OE is currently a postdoctoral fellow with the Research Group for
Evidence-Based Public Health (BIPS GmbH/Universität Bremen) and a lecturer
in the Department of Clinical Pharmacy and Pharmacy Management, Nnamdi
Azikiwe University in Nigeria. TJ is a research associate at the Institute for
Research in Operative Medicine, Witten/Herdecke University, Germany. SKL is
the group head of the Research Group for Evidence-Based Public Health
(BIPS GmbH/University of Bremen. SKL is also a Professor in the Institute for
Public Health and Nursing Research—IPP, Health Sciences Bremen, University
of Bremen, Bremen, Germany.
Acknowledgements
There are no acknowledgements to declare. All authors confirm that no
funding has been provided for this project.
Author details
1Public Health, University Hospital Düsseldorf, Düsseldorf, Germany. 2Surgical
Department, Klinikum Frankfurt Höchst, Frankfurt, Germany. 3Collaborative
Sweiti et al. Systematic Reviews  (2015) 4:171 Page 4 of 5
Research Group for Evidence-Based Public Health, Department of Prevention
and Evaluation, Leibniz Institute for Prevention Research and Epidemiology -
BIPS, Bremen, Germany. 4Department of Clinical Pharmacy and Pharmacy
Management, Nnamdi Azikiwe University, Awka, Nigeria. 5Department for
Evidence-based health services research, Institute for Research in Operative
Medicine, Witten/Herdecke University, Witten, Germany. 6Institute for Public
Health, Health Sciences Bremen, University of Bremen, Bremen, Germany.
Received: 13 August 2015 Accepted: 9 November 2015
References
1. Centers for Disease Control and Prevention. 2014 Ebola outbreak in West
Africa—case counts. August 2015. http://www.cdc.gov/vhf/ebola/outbreaks/
2014-west-africa/case-counts.html. Accessed 27 October 2015.
2. World Health Organization. Ebola virus disease fact sheet No. 103. April
2015. http://www.who.int/mediacentre/factsheets/fs103/en. Accessed 10
August 2015.
3. Enserink M. Debate erupts on repurposed drugs for Ebola. Science. 2014;
345:718–9.
4. Oprea TI, Mestres J. Drug repurposing: far beyond new targets for old
drugs. AAPS J. 2012;14(4):759–63. doi:10.1208/s12248-012-9390-1.
5. Veljkovic V, Loiseau PM, Figadere B, Glisic S, Veljkovic N, Perovic VR, et al.
Virtual screen for repurposing approved and experimental drugs for
candidate inhibitors of EBOLA virus infection. F1000Res. 2015;4:34. doi:10.
12688/f1000research.6110.1.
6. Lai KY, Ng WYG, Cheng FF. Human Ebola virus infection in West Africa: a
review of available therapeutic agents that target different steps of the life
cycle of Ebola virus. Infect Dis Poverty. 2014;3:43. doi:10.1186/2049-9957-3-43.
7. Madrid PB, Chopra S, Manger ID, et al. A Systematic Screen of FDA-
Approved Drugs for Inhibitors of Biological Threat Agents. Yu X, ed. PLoS
ONE. 2013;8(4):e60579. doi:10.1371/journal.pone.0060579
8. DiMasi JA, Grabowski HG, Hansen RW. The cost of drug development. New
Engl J Med. 2015;372(20):1972.
9. Pollack A. Fast track on drug for Ebola has faltered. NYTimes.com. 2015.
http://www.nytimes.com/2015/01/23/business/fast-track-on-drug-for-ebola-
has-faltered.html. Accessed August 10, 2015.
10. Kupferschmidt K. Ebola vaccine tests needlessly delayed, researchers claim.
Sciencemag.org. 2014. http://news.sciencemag.org/africa/2014/09/ebola-
vaccine-tests-needlessly-delayed-researchers-claim. Accessed August 8, 2015.
11. Wilson JA, Bosio CM, Hart MK. Ebola virus: the search for vaccines and
treatments. Cell Mol Life Sci. 2001;58(12-13):1826–41.
12. Ströher U, Feldmann H. Progress towards the treatment of Ebola
haemorrhagic fever. Expert Opin Investig Drugs. 2006;15(12):1523–35.
13. Gene OG, Julia BE, Vanessa MR, Victoria WJ, Thomas GW, Lisa HE. Drug
targets in infections with Ebola and Marburg viruses. Infect Disord Drug
Targets. 2009;9(2):191–200.
14. Olszanecki R, Gawlik G. Pharmacotherapy of Ebola hemorrhagic fever: a brief
review of current status and future perspectives. Folia Med Cracov. 2014;
54(3):67–77.
15. Choi JH, Croyle MA. Emerging targets and novel approaches to Ebola virus
prophylaxis and treatment. BioDrugs. 2013;27(6):565–83. doi:10.1007/s40259-
013-0046-1.
16. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al.
Preferred reporting items for systematic review and meta-analysis protocols
(PRISMA-P) 2015 statement. Syst Rev. 2015;4:1. doi:10.1186/2046-4053-4-1.
17. Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M,
Langendam MW. SYRCLE’s risk of bias tool for animal studies. BMC Med Res
Methodol. 2014;14:43. doi:10.1186/1471-2288-14-43. Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Sweiti et al. Systematic Reviews  (2015) 4:171 Page 5 of 5
